Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
An orally delivered GLP-1 analog coformulated with the absorption enhancer SNAC achieves transcellular-directed absorption in the stomach.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Yet, its adoption is restricted by a complicated dosing protocol that necessitates administration while fasting with water, as well as the avoidance of food or medications for a minimum of 30 min afterward. Such requirements reduce convenience and compromise adherence in routine practice [11, 16].”
From Efficacy and Safety of Orforglipron in Obese Adults With or Without Diabetes: A Systematic Review and Meta‐Analysis (2025) · cites this paper as [16]
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 1×
“Pharmacologically, long-acting GLP-1 receptor agonists (GLP-1RAs) exhibit glucoregulatory functions via a triumvirate of mechanisms, namely, stimulation of insulin release in a glucose-dependent manner, suppression of glucagon activity during hyperglycemia, and a minor delay of gastric emptying resulting in slower glu…”
BackgroundDiscovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105 · cited 1×
“In line with this, recent advancements in fatty acid acylation– based protraction technology have provided the possibility of achieving extended plasma half-lives (t1⁄2) without increasing molecular size, leading to the discovery of semaglutide, a GLP-1 analog with a t1⁄2 of ~1 week in humans (8).”
BackgroundSelf-citationThe arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961 · cited 1×
“In addition, GLP-1 promotes satiety and reduces energy intake by virtue of its neurotransmitter role in brainstem-hypothalamus pathways signaling satiety (3, 4), and some long-acting GLP-1RAs including semaglutide have shown cardiovascular risk reduction (5, 6).”
BackgroundSelf-citationIncretin-based therapies for type 2 diabetes mellitus
Lovshin, J. A., & Drucker, D. J. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.48 · Cited by 649
Davies, M., Pieber, T. R., Hartoft-Nielsen, M.-L., Hansen, O. K. H., Jabbour, S., & Rosenstock, J. (2017) · JAMA · doi:10.1001/jama.2017.14752 · Cited by 506
Self-citationpH stability and activity curves of pepsin with special reference to their clinical importance.
Piper, D. W., & Fenton, B. H. (1965) · Gut · doi:10.1136/gut.6.5.506 · Cited by 385
Intestinal permeation enhancers for oral peptide delivery
Maher, S., Mrsny, R. J., & Brayden, D. J. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.06.005 · Cited by 381
Cited by
Items 201–300 of 599
Shi, Y., Yin, M., Song, Y., Wang, T., Guo, S., Zhang, X., Sun, K., & Li, Y. (2020) · Journal of Biomaterials Applications · doi:10.1177/0885328220947889 · Cited by 25
The Centenary of the Discovery of Insulin: An Update on the Quest for Oral Delivery
Brayden, D. J. (2021) · Frontiers in Drug Delivery · doi:10.3389/fddev.2021.726675 · Cited by 25
Therapeutic peptides and proteins: Status and developments in drug delivery
Hornsby, B. D., Lee, C. H., Steele, C. A., Tuekpe, J. K. K., & Lim, C. S. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114895 · Cited by 25
Kalra, S., Das, S., & Zargar, A. H. (2022) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_522_21 · Cited by 25
Qi, Y., Jin, M., Li, Q., Wu, Q., Liao, Z., Wei, M., Fan, X., Yang, Q., Tian, X., Battaglia, G., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.07.035 · Cited by 24
Novel Approaches for the Management of Type 2 Diabetes Mellitus: An Update
Kumar, A., Mazumder, R., Rani, A., Pandey, P., & Khurana, N. (2023) · Current Diabetes Reviews · doi:10.2174/0115733998261903230921102620 · Cited by 24
Bonora, B. M., Russo, G. T., Leonetti, F., Strazzabosco, M., Nollino, L., Aimaretti, G., Giaccari, A., Broglio, F., Consoli, A., Avogaro, A., et al. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02309-2 · Cited by 24
Regional Intestinal Drug Permeability and Effects of Permeation Enhancers in Rat
Dahlgren, D., Cano-Cebrián, M. J., Olander, T., Hedeland, M., Sjöblom, M., & Lennernäs, H. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12030242 · Cited by 24
Majanović, S. K., Belančić, A., Bukša, I., Morić, N., & Rahelić, D. (2024) · Diabetology · doi:10.3390/diabetology5010005 · Cited by 23
Mortensen, J. S., Bohr, S. S.-R., Harloff-Helleberg, S., Hatzakis, N. S., Saaby, L., & Nielsen, H. M. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.09.034 · Cited by 23
Hossain, S., Kneiszl, R., & Larsson, P. (2023) · Nanoscale · doi:10.1039/d3nr05571j · Cited by 22
Tahan, M. A. A., Al-Khattawi, A., & Russell, C. A. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107205 · Cited by 22
Do Macrocyclic Peptide Drugs Interact with Bile Salts under Simulated Gastrointestinal Conditions?
Dening, T. J., Douglas, J. T., & Hageman, M. J. (2021) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.1c00309 · Cited by 22
Pinto, S., Viegas, J. S. R., Cristelo, C., Pacheco, C., Barros, S., Buckley, S. T., Garousi, J., Gräslund, T., Santos, H. A., & Sarmento, B. F. C. C. (2024) · ACS Nano · doi:10.1021/acsnano.4c11172 · Cited by 22
Self-citationHaggag, A. Z., Xu, J., Butcher, L., Pagnussat, S., Davies, G., Lundqvist, S., Wang, W., van Zuydam, N. R., Nelander, K., Jha, A., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16047 · Cited by 22
Subedi, L., Bamjan, A. D., Phuyal, S., Shim, J., Cho, S., Seo, J. B., Chang, K.-Y., Byun, Y., Kweon, S., & Park, J. W. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.12.039 · Cited by 22
Oral Delivery Strategies for Biological Drugs
Zeng, H., Ma, M., Peng, X., Xie, Y., Xie, A., Deng, B., Ouyang, J., Tao, W., Yang, P., & He, W. (2025) · Small Methods · doi:10.1002/smtd.202401355 · Cited by 23
Incretins and the cardiovascular system: bridging digestion with metabolism
Avogaro, A., & Fadini, G. P. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00166-4 · Cited by 21
Hossain, S., Parrow, A., Kabedev, A., Kneiszl, R., Leng, Y., & Larsson, P. (2021) · Processes · doi:10.3390/pr10010029 · Cited by 21
Uhl, P., Bajraktari‐Sylejmani, G., Witzigmann, D., Bay, C., Zimmermann, S., Burhenne, J., Weiß, J., Haefeli, W. E., & Sauter, M. (2023) · Advanced Therapeutics · doi:10.1002/adtp.202300021 · Cited by 21
Biology and Clinical Use of Glucagon-Like Peptide-1 Receptor Agonists in Vascular Protection
Yau, K., Odutayo, A., Dash, S., & Cherney, D. Z. I. (2023) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2023.07.007 · Cited by 22
Intestinal Lymphatic Biology, Drug Delivery, and Therapeutics: Current Status and Future Directions
Reddiar, S. B., Xie, Y., Abdallah, M., Han, S., Hu, L., Feeney, O. M., Gracia, G., Anshabo, A., Lu, Z., Farooq, M. A., et al. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001159 · Cited by 21
Tomono, T., Yagi, H., Ukawa, M., Ishizaki, S., Miwa, T., Nonomura, M., Igi, R., Kumagai, H., Miyata, K., Tobita, E., et al. (2020) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2020.07.003 · Cited by 21
Bain, E. K., & Bain, S. C. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14487 · Cited by 20
Chen, H., Lu, Y., Shi, S., Zhang, Q., Cao, X., Sun, L., An, D., Zhang, X., Kong, X., & Liu, J. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03265-3 · Cited by 20
Lu, Y., Wu, L., Lin, M., Bao, X., Zhong, H., Peng, K., Dai, Q., Yang, Q., Tang, X., Xu, W., et al. (2023) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2023.09.003 · Cited by 20
New insights into nanomedicines for oral delivery of glucagon‐like peptide‐1 analogs
Pinto, S., Santos, H. A., & Sarmento, B. F. C. C. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1952 · Cited by 20
Kim, G. L., Song, J. G., & Han, H.-K. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16070886 · Cited by 20
Niu, Z., Zara, D. L., Blaabjerg, L. I., Pessi, J., Raptis, K., Toftlev, A., Sauter, M., Christophersen, P. C., Bardonnet, P.-L., Andersson, V., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.11.078 · Cited by 20
Self-citationMcCartney, F., Perinelli, D. R., Tiboni, M., Cavanagh, R. J., Lucarini, S., Palmieri, G. F., Casettari, L., & Brayden, D. J. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120593 · Cited by 20
The evolving landscape of obesity pharmacotherapy
Petersen, J., Finan, B., Johansen, V. B. I., Müller, T. D., & Clemmensen, C. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01427-1 · Cited by 19
Ishii, H., Hansen, B. B., Langer, J., & Horio, H. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00985-w · Cited by 19
Bao, D., Xie, X., Cheng, M., Zhang, K., Yue, T., Liu, A., Fang, W., Wei, Y., Zheng, H., Piao, J., et al. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121918 · Cited by 19
Kweon, S., Lee, J.-H., Yang, S.-B., Park, S. J., Subedi, L., Shim, J., Cho, S., Choi, J. U., Byun, Y., Park, J., et al. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00421-7 · Cited by 19
Varin, E. M., McLean, B. A., & Lovshin, J. A. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.08.011 · Cited by 19
Selective release of gastrointestinal hormones induced by an orally active GPR39 agonist
Grunddal, K. V., Diep, T. A., Petersen, N., Tough, I. R., Skov, L. J., Liu, L.-Z., Buijink, J. A., Mende, F., Jin, C., Jepsen, S. L., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101207 · Cited by 19
Meier, J. J., Granhall, C., Hövelmann, U., Navarria, A., Plum‐Mörschel, L., Ramesh, C. K., Tannapfel, A., & Kapitza, C. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14632 · Cited by 20
Wu, J., Zhou, R., Zhang, Q., Zhang, Q., Qin, H., Ye, Z., Xu, Y., Feng, S., Shu, C., Shen, Y., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15383 · Cited by 18
Neutralizing Effect of Synthetic Peptides toward SARS-CoV-2
Souza, P. F. N., van Tilburg, M. F., Mesquita, F. P., Amaral, J. L., Lima, L. B., Montenegro, R. C., Lopes, F. E. S., Martins, R. X., Vieira, L., Farias, D. F., et al. (2022) · ACS Omega · doi:10.1021/acsomega.2c02203 · Cited by 18
Jones, B. J., BURADE, V. S., Akalestou, E., Manchanda, Y., Ramchunder, Z., Carrat, G., Nguyen‐Tu, M., Marchetti, P., Piemonti, L., Leclerc, I., et al. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14794 · Cited by 17
A self-unfolding proximity enabling device for oral delivery of macromolecules
Ghavami, M., Pedersen, J., Kjeldsen, R. B., Alstrup, A. K. O., Zhang, Z., Koulianou, V., Palmfeldt, J., Vorup‐Jensen, T., Thamdrup, L. H. E., & Boisen, A. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.07.041 · Cited by 17
Obesity – Standards, trends and advances
Gołacki, J., & Matyjaszek‐Matuszek, B. (2024) · Advances in Medical Sciences · doi:10.1016/j.advms.2024.04.001 · Cited by 18
Fiore, V., Carbotta, G., Barraco, S., Falasca, P., Aricò, C. N., & Barucca, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16174 · Cited by 17
Mosenzon, O., Miller, E. M., & Warren, M. L. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1800286 · Cited by 16
Østergaard, S. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2601113 · Cited by 16
Kweon, S., Park, S. J., Lee, H. K., Kang, S. H., Chang, K.-Y., Choi, J. U., Park, J., Shim, J., Park, J. W., & Byun, Y. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s442617 · Cited by 16
Rebollo, R., Niu, Z., Blaabjerg, L. I., Zara, D. L., Juel, T., Pedersen, H. D., Andersson, V., Benova, M., Krogh, C., Pons, R., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.11.036 · Cited by 16
Self-citationEvaluation in pig of an intestinal administration device for oral peptide delivery
Berg, S., Uggla, T., Antonsson, M., Nunes, S. F., Englund, M., Rosengren, L., Fahraj, M., Wu, X., Govender, R., Söderberg, M. P., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.12.011 · Cited by 16
Cyclic Peptide Linker Design and Optimization by Molecular Dynamics Simulations
Yu, L., Barros, S. A., Sun, C., & Somani, S. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c01359 · Cited by 16
Rational design of oral delivery nanosystems for hypoglycemic peptides
Peng, T., Shao, X., Li, L., Liu, H., Song, W., Hou, J., Zhong, H., Ding, Y., & Huang, Y. (2023) · Nano Today · doi:10.1016/j.nantod.2023.102031 · Cited by 15
Evaluating the oral delivery of GalNAc-conjugated siRNAs in rodents and non-human primates
Yu, M., Qin, J., Liu, X., Ramsden, D., Williams, B., Zlatev, I., Guenther, D. C., Matsuda, S., Tymon, R. E., Darcy, J., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae350 · Cited by 15
Forst, T. M., Block, C. E. M. D., Prato, S. D., Frías, J. P., Lautenbach, A., Ludvik, B. H., Marinez, M., Mathieu, C., Müller, T. D., & Schnell, O. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16247 · Cited by 15
Synthetic antimicrobial peptides for controlling fungi in foods
Souza, P. F. N. (2022) · Current Opinion in Food Science · doi:10.1016/j.cofs.2022.100819 · Cited by 15
Tang, Y., Arbaugh, B. M., Park, H., Scher, H. B., Bai, L., Mao, L., & Jeoh, T. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.104063 · Cited by 15
Investigation of FcRn‐Mediated Transepithelial Mechanisms for Oral Nanoparticle Delivery Systems
Yu, Y., Wu, Z., Wu, J., Shen, X., Wu, R., Zhou, M., Li, L., & Huang, Y. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100145 · Cited by 15
Future Perspectives of Oral Delivery of Next Generation Therapies for Treatment of Skin Diseases
Søgaard, P. P., Lind, M. L., Christiansen, C. R., Petersson, K., Clauss, A., & Caffarel–Salvador, E. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13101722 · Cited by 15
Rivera, K. R., Pessi, J., Andersson, V., Gustafsson, H., Gluud, L. L., & Buckley, S. T. (2023) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2023.106386 · Cited by 15
Self-citationA new opening for orally taken peptide drugs
Artursson, P., & Lundquist, P. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-019-0513-1 · Cited by 15
Practical guidance for use of oral semaglutide in primary care: a narrative review
Morales, J., Shubrook, J. H., & Skolnik, N. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1788340 · Cited by 14
Rakhat, Y., Wang, L., Han, W., Rustemova, A., Kulzhanova, N., Yamada, Y., Yabe, D., Seino, Y., & Yada, T. (2023) · Nutrients · doi:10.3390/nu15173765 · Cited by 14
Morieri, M. L., Candido, R., Frontoni, S., Disoteo, O., Solini, A., Fadini, G. P., for the PIONEERING EXPERIENCE study group, Bellanti, F., Caprio, M., Cutolo, M., et al. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01490-6 · Cited by 14
Xie, P., Abildlund, M. T., Bækdal, T. A., He, X., Lyauk, Y. K., Patted, U. R. H., Zu, N., & Shi, A. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15624 · Cited by 14
Self-citationAdvances in the transport of oral nanoparticles in gastrointestinal tract
Song, T., Yuan, L., Wang, J., Li, W., & Sun, Y. (2024) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2024.114321 · Cited by 14
Permeation Enhancer‐based Ionogel Shows Remarkable Potential for Oral Insulin Delivery
Raptis, K., Heade, J., da Cunha, C. F. B., van de Weert, M., Saaby, L., Rønholt, S., & Nielsen, H. M. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202500946 · Cited by 14
Ariaee, A., Noueihad, K., Hunter, A., Wignall, A. D., Wardill, H. R., Davies, M. R., Prestidge, C. A., & Joyce, P. M. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114711 · Cited by 14
Will oral semaglutide be a game-changer in the management of type 2 diabetes in primary care?
Seidu, S., Mellbin, L., Kaiser, M., & Khunti, K. (2020) · Primary care diabetes · doi:10.1016/j.pcd.2020.07.011 · Cited by 15
Interactions of oral permeation enhancers with lipid membranes in simulated intestinal environments
Larsen, N. W., Kostrikov, S., Hansen, M. B., Hjørringgaard, C. U., Larsen, N. B., Andresen, T. L., & Kristensen, K. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.123957 · Cited by 14
Enhanced oral and pulmonary delivery of biomacromolecules via amplified transporter targeting
Xiao, X., Zhang, L., Ni, M., Liu, X., Xing, L., Wu, L., Zhou, Z., Li, L., Wen, J., & Huang, Y. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.04.026 · Cited by 14
Candido, R., Loreto, C. D., Desenzani, P., Pantanetti, P., Romano, C., Settembrini, S., Solerte, S. B., & Fadini, G. P. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01625-3 · Cited by 14
Araki, E., Terauchi, Y., Watada, H., Deenadayalan, S., Christiansen, E., Horio, H., & Kadowaki, T. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14536 · Cited by 14
Eliasson, B., Ericsson, Å., Fridhammar, A., Nilsson, A., Persson, S., & Chubb, B. (2022) · PharmacoEconomics - Open · doi:10.1007/s41669-021-00317-z · Cited by 14
Xu, Y., Amakye, W. K., Xiao, G., Liu, X., Ren, J., & Wang, M. (2022) · Food Chemistry · doi:10.1016/j.foodchem.2022.134059 · Cited by 13
Investigating the Association Between Diet-Induced “Leaky Gut” and the Development of Prediabetes
Dimba, N. R., Mzimela, N., Mosili, P., Ngubane, P. S., & Khathi, A. (2023) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2181-6664 · Cited by 13
Ling, J., Schroder, R. V., Wuelfing, W. P., Higgins, J. P., Kesisoglou, F., Templeton, A. C., & Su, Y. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c01061 · Cited by 13
Fan, X., Jiang, K., Zhao, Y., Lee, B. T., Geng, F., Brelen, M. E., Lu, W., & Wei, G. (2025) · Advanced Science · doi:10.1002/advs.202410744 · Cited by 14
Advances in Oral Biomacromolecule Therapies for Metabolic Diseases
Jiao, Q., Huang, Y., He, J., & Xu, Y. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17020238 · Cited by 13
Herbster, L., Pander, G., Böhmann, M. B., Eisenzapf, T., Wohlfart, S., Mühlberg, E., Mier, W., Fricker, G., & Uhl, P. (2025) · Nano Select · doi:10.1002/nano.70010 · Cited by 13
Oral Treatment of Obesity by GLP-1 and Its Analogs
Holler, N., Ruseska, I., Schachner-Nedherer, A.-L., Zimmer, A., & Petschacher, C. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17121596 · Cited by 13
Lawrence, S. A., Blankenship, R. L., Brown, R. M., Estwick, S. A., Ellis, B., Thangaraju, A., & Datta‐Mannan, A. (2020) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2020.115942 · Cited by 13
O’Dwyer, P. J., Box, K. J., Dressman, J., Griffin, B. T., Henze, L. J., Litou, C., Pentafragka, C., Statelova, M., Vertzoni, M., & Reppas, C. I. (2021) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgaa055 · Cited by 13
Weller, A., Hansen, M. B., Marie, R., Hundahl, A. C., Hempel, C., Kempen, P. J., Frandsen, H. L., Parhamifar, L., Larsen, J. B., & Andresen, T. L. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.965200 · Cited by 13
Panou, D. A., Pedersen, S. F., Kristensen, M., & Nielsen, H. M. (2023) · Frontiers in Drug Delivery · doi:10.3389/fddev.2023.1221628 · Cited by 13
Milián-Guimerá, C., Vittorio, L. D., McCabe, R., Göncü, N., Krishnan, S., Thamdrup, L. H. E., Boisen, A., & Ghavami, M. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16010081 · Cited by 13
Kamei, N., Kawano, S., Abe, R., Hirano, S., Ogino, H., Tamiwa, H., & Takeda‐Morishita, M. (2020) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2020.08.001 · Cited by 13
Recent strategies driving oral biologic administration
Alotaibi, B. S., Buabeid, M. A., Ibrahim, N. A., Kharaba, Z. J., Ijaz, M., & Murtaza, G. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1990044 · Cited by 13
Burshtein, G., Itin, C., TANG, J. C. Y., Galitzer, H., Fraser, W. D., & Schwartz, P. (2021) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2021.100097 · Cited by 13
Singh, A. K., Singh, R., & Misra, A. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102436 · Cited by 13
Combined Antibiofilm Activity of Synthetic Peptides and Antifungal Drugs Against Candida Spp.
Bezerra, L. P., Silva, A. F. B., Santos‐Oliveira, R., Alencar, L. M. R., Amaral, J. L., Neto, N. A. S., Silva, R. G. G., Belém, M. O., de Andrade, C. R., Oliveira, J. T., et al. (2022) · Future Microbiology · doi:10.2217/fmb-2022-0053 · Cited by 13
Li, Y., & Zhu, C. (2020) · Molecules · doi:10.3390/molecules25081957 · Cited by 13
Overcoming Cellular and Systemic Barriers to Design the Next Wave of Peptide Therapeutics
Hochman, J. H., Sawyer, T. K., & Duggal, R. (2021) · Methods in pharmacology and toxicology · doi:10.1007/978-1-0716-1250-7_10 · Cited by 12
Engineering of a Biologically Active Glycosylated Glucagon-Like Peptide-1 Analogue
Chandrashekar, C., Lin, F. W., Nishiuchi, Y., Mohammed, S. F., White, B. F., Arsenakis, Y., Yuliantie, E., Zhao, P., van Dun, S., Koijen, A., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00093 · Cited by 12
He, L., Li, A., Yu, P., Qin, S., Tan, H., Zou, D., Wu, H., & Wang, S. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107461 · Cited by 12
Glucagon-like peptide-1 receptor agonists to improve cardiorenal outcomes: data from FLOW and beyond
Faruque, L. I., Yau, K., & Cherney, D. Z. I. (2025) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000001066 · Cited by 12
Innovative Molecules and Delivery Technologies Enabling the Future of GLP-1-based Therapies
Xu, Y., Drucker, D. J., Traverso, G., & Beloqui, A. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf027 · Cited by 13
Design of Potent and Proteolytically Stable Biaryl-Stapled GLP-1R/GIPR Peptide Dual Agonists
Yang, Y., Lee, C., Reddy, R. R., Huang, D. J., Zhong, W., Nguyen-Tran, V. T. B., Shen, W., & Lin, Q. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.2c00175 · Cited by 12
Efficacy and Safety of Oral Semaglutide in the Treatment of Type 2 Diabetes: A Meta‐Analysis
Zhang, L., Hua, Z., Fang, Z., Wei, J., & Yang, L. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2483 · Cited by 12
Pantanetti, P., Ronconi, V., Sguanci, M. E., Palomares, S. M., Mancin, S., Tartaglia, F. C., Cangelosi, G., & Petrelli, F. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164752 · Cited by 12
Semaglutide injection for the treatment of adults with type 2 diabetes
Chudleigh, R. A., & Bain, S. C. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1776108 · Cited by 13
Novel Drugs for Diabetes Therapy
Heise, T. (2022) · Handbook of experimental pharmacology · doi:10.1007/164_2021_574 · Cited by 12
Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond
Viljoen, A., & Bain, S. C. (2023) · Endocrinology and Metabolism · doi:10.3803/enm.2022.1642 · Cited by 11
“SNAC increases the local pH in the stomach reducing acid degradation and allowing for transcellular absorption of semaglutide in the stomach (unlike most drugs which are absorbed in the small intestine).”
Metadata
- Authors
- Buckley, S. T., Bækdal, T. A., Vegge, A., Maarbjerg, S. J., Pyke, C., Ahnfelt-Rønne, J., Madsen, K. G., Schéele, S. G., Alanentalo, T., Kirk, R. K., Pedersen, B. L., Skyggebjerg, R. B., Benie, A. J., Strauss, H. M., Wahlund, P.-O., Bjerregaard, S., Farkas, E., Fekete, C., Søndergaard, F. L., Borregaard, J., Hartoft-Nielsen, M.-L., & Knudsen, L. B.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Novo Nordisk A/S, 2760 Måløv, Denmark.
- HUN-REN Institute of Experimental Medicine (HU)
- Tufts Medical Center (US)
- Novo Nordisk A/S, 2860 Søborg, Denmark.
- Corresponding author
- Buckley, Stephen T.
- Bækdal, Tine A.
- Vegge, Andreas
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2018-11-14
- Volume
- 10
- Issue
- 467
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2901306081
- Cited by
- 553
- References
- 40
- Citations by year
- 2026: 84 · 2025: 89 · 2024: 74 · 2023: 53 · 2022: 73 · 2021: 77 · 2020: 69 · 2019: 32 · 2018: 1
- FWCI
- 21.09
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novo Nordisk
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- semaglutide, GLP-1 receptor agonists, SNAC, gastric absorption, oral drug delivery, tablet formulation, tight junctions
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Administration, Oral, Adolescent, Adult, Aged, Animals, Cell Membrane, Dogs, Glucagon-Like Peptides, Epithelial Cells, Gastric Mucosa, Humans, Hydrogen-Ion Concentration, Intestinal Absorption, Male, Middle Aged, Stomach, Time Factors, Rats, Glucagon-Like Peptide 1, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.